RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SkinBioTherapeutics Stock

SkinBioTherapeutics Equity 2025

SkinBioTherapeutics Equity

1.99 M GBP

Ticker

SBTX.L

ISIN

GB00BF33H870

WKN

A2DPW8

In 2025, SkinBioTherapeutics's equity was 1.99 M GBP, a -19.41% increase from the 2.48 M GBP equity in the previous year.

SkinBioTherapeutics Aktienanalyse

What does SkinBioTherapeutics do?

SkinBioTherapeutics PLC is an innovative biotechnology company specialized in the development of skincare products. The company was founded in 2016 in Manchester, United Kingdom, and has since been led by a team of experienced scientists and entrepreneurs. The company's CEO, Dr. Catherine O'Neill, founded SkinBioTherapeutics PLC with the goal of developing innovative skincare products based on the latest scientific findings. The company focuses on the development of products using probiotic bacteria, which have been found to influence the immune system. SkinBioTherapeutics PLC is divided into three divisions: skincare, medical applications, and cosmetics. The skincare division develops products specifically tailored to the needs of individuals with sensitive and problematic skin, aiming to improve the skin's immune system and reduce inflammation and irritation. The medical applications division focuses on the use of probiotic bacteria in treating skin conditions such as psoriasis, eczema, and acne. The cosmetics division, under the brand "SkinBiotix," develops products to improve skin health and appearance. Currently, SkinBioTherapeutics PLC offers several products, including SkinBiotix Balance, a skincare cream for sensitive and problematic skin, SkinBiotix Cleanse, a gentle water-based cleanser, and SkinBiotix Strengthen, a rich moisturizer for dry and problematic skin. With its unique technology platform and strong emphasis on research and development, SkinBioTherapeutics PLC is well-positioned to continue growing and bringing its innovative products to market. SkinBioTherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing SkinBioTherapeutics's Equity

SkinBioTherapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SkinBioTherapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SkinBioTherapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SkinBioTherapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SkinBioTherapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SkinBioTherapeutics stock

What is the equity of SkinBioTherapeutics this year?

SkinBioTherapeutics has equity of 1.99 M GBP this year.

What was the equity of SkinBioTherapeutics compared to the previous year?

The equity of SkinBioTherapeutics has increased/decreased by -19.41% decreased compared to the previous year.

What impact does a high equity have on investors of SkinBioTherapeutics?

A high equity is advantageous for investors of SkinBioTherapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of SkinBioTherapeutics?

A low equity can be a risk for investors of SkinBioTherapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of SkinBioTherapeutics affect the company?

An increase in equity of SkinBioTherapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of SkinBioTherapeutics affect the company?

A reduction in equity of SkinBioTherapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of SkinBioTherapeutics?

Some factors that can affect the equity of SkinBioTherapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of SkinBioTherapeutics so important for investors?

The equity of SkinBioTherapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can SkinBioTherapeutics take to change the equity?

To change equity, SkinBioTherapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does SkinBioTherapeutics pay?

Over the past 12 months, SkinBioTherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SkinBioTherapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of SkinBioTherapeutics?

The current dividend yield of SkinBioTherapeutics is .

When does SkinBioTherapeutics pay dividends?

SkinBioTherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SkinBioTherapeutics?

SkinBioTherapeutics paid dividends every year for the past 0 years.

What is the dividend of SkinBioTherapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is SkinBioTherapeutics located?

SkinBioTherapeutics is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von SkinBioTherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SkinBioTherapeutics from 1/21/2025 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 1/21/2025.

When did SkinBioTherapeutics pay the last dividend?

The last dividend was paid out on 1/21/2025.

What was the dividend of SkinBioTherapeutics in the year 2024?

In the year 2024, SkinBioTherapeutics distributed 0 GBP as dividends.

In which currency does SkinBioTherapeutics pay out the dividend?

The dividends of SkinBioTherapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SkinBioTherapeutics

Our stock analysis for SkinBioTherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SkinBioTherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.